Recurrent Glioblastoma Multiforme

Oncology
4
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
2 programs
2
Panzem NCDPhase 21 trial
Panzem Nanocrystal Colloidal DispersionPhase 21 trial
Active Trials
NCT00481455CompletedEst. Oct 2008
NCT00306618CompletedEst. Dec 2008
Teva
TevaIsrael - Petach Tikva
1 program
1
TP-38Phase 22 trials
Active Trials
NCT00104091Completed56Est. Jun 2007
NCT00071539Completed56Est. Jul 2006
Genentech
GenentechCA - Oceanside
1 program
1
temozolomide and bevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00883298Completed30Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Genentechtemozolomide and bevacizumab
CASI PharmaceuticalsPanzem NCD
CASI PharmaceuticalsPanzem Nanocrystal Colloidal Dispersion
TevaTP-38
TevaTP-38

Clinical Trials (5)

Total enrollment: 142 patients across 5 trials

NCT00883298Genentechtemozolomide and bevacizumab

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Start: Apr 2009Est. completion: Dec 201430 patients
Phase 2Completed
NCT00481455CASI PharmaceuticalsPanzem NCD

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

Start: Apr 2007Est. completion: Oct 2008
Phase 2Completed
NCT00306618CASI PharmaceuticalsPanzem Nanocrystal Colloidal Dispersion

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

Start: Jan 2006Est. completion: Dec 2008
Phase 2Completed
NCT00104091TevaTP-38

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Start: Dec 2004Est. completion: Jun 200756 patients
Phase 2Completed
NCT00071539TevaTP-38

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Start: Oct 2003Est. completion: Jul 200656 patients
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)